1. Introduction {#sec1}
===============

Environmental exposures and genetic predisposition are hypothesized to interact to result in the expression of autoimmune rheumatic diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and systematic autoimmune rheumatic diseases (SARDs) \[[@B1]\], as well as other immune-mediated diseases such as inflammatory bowel disease \[[@B2]\] and multiple sclerosis \[[@B3]\]. Identifying modifiable risk factors for disease development and prognosis is important to reduce the substantial impact and burden of these chronic diseases in society.

Air pollution is a plausible risk factor for autoimmune disease development. Other inhalants such as tobacco smoke and silica are strongly associated with the development of RA, related to their ability to directly interact with alveolar tissue \[[@B4], [@B5]\]. Air pollution has been demonstrated to be able to directly stimulate an inflammatory response \[[@B6]\] and indirectly alter the microbiome \[[@B7]\]. A relationship between particulate matter exposure and elevations in inflammatory marker levels has been described \[[@B8]--[@B11]\]. As randomized controlled trials to assess directly for causation between air pollutant exposures and disease development in humans are not feasible, we must rely on observational studies to assess for evidence of associations. Fortunately, several methods to estimate air pollutant exposure exist. A variety of air pollutants from industrial and private sources are measurable at fixed-site continuous monitoring stations that collect hourly mean levels of criteria air pollutants, including particulate matter \<2.5 *μ*m in size (PM~2.5~), particulate matter \<10 *μ*m in size (PM~10~), sulfur dioxide (SO~2~), nitrogen dioxide (NO~2~), carbon monoxide (CO), and ozone (O~3~). The hourly data can then be averaged to obtain defined temporal estimates for the region (e.g., a city). Land use regression models use Geographic Information System (GIS) to estimate air pollutant exposure through a combination of land use, traffic, population density, physical geography, and meteorology across an area \[[@B12]\] and predict concentrations at a defined site, such as an individual\'s location of residence determined by postal code \[[@B13]\]. Inverse distance weighting (IDW) uses the general principle of interpolation, where values at a site are estimated based on distance from a measured value at another point (e.g., a monitoring station) under the presumption of reducing pollutant levels with increasing distance \[[@B14]\]. Finally, remote sensing through satellite imaging yields estimates across broad geographic areas.

Our objective was to identify studies estimating associations between exposure to the air pollutants listed above and the risk of development of select rheumatic diseases. This included inflammatory arthritis conditions such as RA and JIA, as well as SARDs and individual diseases of autoimmune myositis, systemic lupus erythematosus (SLE), scleroderma, and vasculitis.

2. Methods {#sec2}
==========

2.1. Search Strategy {#sec2.1}
--------------------

MEDLINE (1946 to September 2016) and EMBASE (1980 to 2016, week 37) databases were searched using MeSH terms and keywords for rheumatic diseases (RA, SLE, JIA, inflammatory myositis, scleroderma, vasculitis, and SARDs) in relation to exposure to measured air pollutants \[[@B15]\] (Search Strategy in Appendix).

2.2. Study Selection {#sec2.2}
--------------------

Three authors (Gavin Sun, Glen Hazlewood, and Cheryl Barnabe) independently completed title and abstract and full-text reviews. Studies were included based on the following criteria: assessing the outcome of a rheumatic disease of interest (RA, JIA, SARDs, and individual diseases of autoimmune myositis, SLE, scleroderma, and vasculitis), individual exposure to ambient air pollutants (PM~2.5~, PM~10~, SO~2~, NO~2~, CO, and O~3~), and having a case-control, case cross-over, or cohort design. Only English language studies were included. The study had to report risk estimates (any of relative risk (RR), hazard ratio (HR), or odds ratio (OR)) with the corresponding 95% confidence intervals (95% CI) or sufficient data for calculation. Reviews, case reports, mechanism studies, and nonhuman studies were excluded.

2.3. Data Extraction and Assessment of Study Quality {#sec2.3}
----------------------------------------------------

Data extraction was performed in duplicate by two authors (Gavin Sun and Cheryl Barnabe). A standard reporting form was developed to extract pertinent information from each study, including the country or region of study, calendar years of study, diagnosis criteria for the rheumatic disease assessed, and the number of patients in case or control groups in each category. The study design and method of assessing air pollutant levels were also extracted. The estimates and their margin of error were extracted. The Newcastle-Ottawa scale \[[@B16]\] was used to assess the quality of the studies relevant to the objective, again in duplicate by two authors (Gavin Sun and Cheryl Barnabe). For case-control studies, quality was assessed for four domains of selection (case definition, representativeness of cases, selection of controls, and definition of controls), two domains of comparability (study controls for the most important factor and any additional important factor), and three domains of exposure (ascertainment of exposure, same method of ascertainment for cases and controls, and the nonresponse rate). For cohort studies, quality is assessed for four domains of selection (representativeness of exposed cohort, selection of the nonexposed cohort, ascertainment of exposure, and demonstration that the outcome of interest was not present at start of study), two domains of comparability (study controls for the most important factor and any additional important factor), and three domains of outcome (method of assessment of outcome, follow-up period, and adequacy of follow-up of cohorts). Points are assigned based on specified levels of quality within each domain to a maximum of 9 points.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Our a priori study protocol intention was to perform meta-analysis on eligible studies. Following the full-text review stage, we determined that pooling was not appropriate given the small number of studies and heterogeneity in methods; thus the studies were summarized qualitatively.

3. Results {#sec3}
==========

3.1. Study Inclusion {#sec3.1}
--------------------

A total of 962 unique publications were identified, of which 27 underwent full-text review, with 8 studies included in our summary \[[@B17]--[@B24]\] ([Figure 1](#fig1){ref-type="fig"}). Individual study characteristics are listed in [Table 1](#tab1){ref-type="table"}.

We identified studies in RA (*n* = 4), SARDs (*n* = 2), and JIA (*n* = 2) populations; no studies were found for SLE, inflammatory myopathies, or scleroderma as unique entities. With the exception of studies from Sweden and Taiwan, all studies were of North American populations. One abstract each in the conditions of ANCA vasculitis \[[@B25]\] and Kawasaki Disease \[[@B26]\] was found, but they did not report risk estimates and thus were not included in the formal synthesis.

3.2. Rheumatoid Arthritis {#sec3.2}
-------------------------

Four studies included subjects with RA (two case-control studies \[[@B18], [@B19]\] and two cohort studies \[[@B17], [@B20]\]) and examined associations with exposure to NO~2~, SO~2~, PM~2.5~, and PM~10~ ([Table 2](#tab2){ref-type="table"}). In Hart et al., 2013, using data from the Nurses\' Health Study and land use regression models, there was no definite evidence for increased RA risk related to a cumulative average exposure to NO~2~, SO~2~, PM~10~, or PM~2.5~ after adjustment for covariates \[[@B20]\]. In Hart et al., 2013, using data from the Swedish Epidemiological Investigation of Rheumatoid Arthritis study and land use regression models, the investigators were unable to demonstrate any increased risk for the development of RA with exposure to NO~2~, PM~10~, or SO~2~ \[[@B19]\]. In the study by De Roos et al., RA definitions were based on physician billing and prescription data; land use regression was used in the estimates for PM~2.5~ and NO~2~ as well as additional pollutants, black carbon and NO, and the inverse distance weighting method was used for PM~10~ and SO~2~ estimates as well as for NO, ozone, and CO \[[@B18]\]. When the RA definition required a specialist-confirmed diagnosis, air pollutant exposure effect estimates were all inversely associated with the development of RA. In this study, residence proximity to roadway was additionally studied as a proxy for air pollutant exposure, with a significantly higher risk for RA for those within 50 metres from a highway compared to those over 150 metres away (OR: 1.37; 95% CI: 1.11 to 1.68). In the study by Chang et al., data from monitoring sites were linked to administrative health data and incident RA cases were studied \[[@B17]\]. No association was found for PM~2.5~ exposure, but a significantly higher risk of incident RA was found in those exposed to the highest NO~2~ levels (adjusted HR for 3rd quartile: 1.53; 95% CI: 1.12 to 2.09; adjusted HR for 4th quartile: 1.52; 95% CI: 1.11 to 2.08).

3.3. Systemic Autoimmune Rheumatic Diseases {#sec3.3}
-------------------------------------------

Bernatsky et al. reported the association between PM~2.5~ exposure and the odds of prevalent SARDs in case-control studies performed in Quebec and Alberta, Canada \[[@B21]\]. Exposure measurement was determined using average residential exposures at diagnosis based on satellite-derived data. In Alberta, a nonlinear association was found. The OR at PM~2.5~ exposures of 6.02 to 6.92 *μ*g/m^3^ was 1.25 (95% Credible Interval (CrI): 1.15 to 1.36), the OR at exposures of 6.92 to 8.11 *μ*g/m^3^ was 1.03 (95% CrI: 0.94 to 1.13), and the OR at exposures of ≥8.12 *μ*g/m^3^ was 1.13 (95% CrI: 1.02 to 1.25) after adjustment for sex, age, urban versus rural residence, and median income. In Quebec, increasing odds for increasing levels of PM~2.5~ exposure were demonstrated, with significant odds at levels of ≥11.81 *μ*g/m^3^. In a study focused on one city in Alberta (Calgary) using land use regression models, exposure to PM~2.5~ appeared to be potentially associated with prevalent SARD (OR: 1.10; 95% CrI: 1.01 to 1.22) in the model adjusted for sex, mean income, age \> 45 years, and interaction between age and sex \[[@B22]\]. No association with NO~2~ was demonstrated (OR: 1.02; 95% CrI: 0.98 to 1.02) \[[@B22]\].

3.4. Juvenile Idiopathic Arthritis {#sec3.4}
----------------------------------

Two North American studies have explored the association between PM~2.5~ and JIA. From a patient population in Utah, 338 cases were identified based on a clinical examination by a rheumatologist. Exposure determination was based on monitoring sites data and no-intercept regression models. RR of 1.60 per 10 *μ*g/m^3^ (95% CI: 1.00 to 2.54) for disease onset was found for children \< 5.5 years of age but the results were imprecise when all ages were included in the analysis (RR: 1.11; 95% CI: 0.85--1.45) \[[@B23]\]. The results were not replicated when studying a broader population in America and Canada with systemic-onset JIA \[[@B24]\].

3.5. Study Quality {#sec3.5}
------------------

The four studies in RA and two studies in SARDs were all deemed to be of high quality on the Newcastle-Ottawa scale in domains of selection, comparability, and exposure in the case-control studies and domains of selection, comparability, and outcome for the cohort study. Both studies in JIA were rated at lower quality, related to the case-crossover design selected. A summary of the quality assessment is found in Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}.

4. Discussion {#sec4}
=============

The goal of our research was to synthesize the published literature on associations between air pollution and the development of rheumatic disease. Air pollution has previously been associated with inflammation and other immune-mediated diseases such as inflammatory bowel disease \[[@B2]\] and multiple sclerosis \[[@B3]\], with the hypothesis built on strong basic science and translational studies \[[@B6], [@B27]\]. We identified relevant studies in RA, SARDs, and JIA conditions. In a cohort study from the USA and a case-control study from Sweden, no association between an increased RA risk and exposure to NO~2~, SO~2~, or PM was detected. In contrast, the cohort study from Taiwan found increased risk of RA with exposure to higher levels of NO~2~. Surprisingly, the case-control study by De Roos et al. did find an increased risk for RA based on proximity of the primary residence to highways but a potential reduced risk of developing RA in relation to air pollutant exposure \[[@B18]\], which is counterintuitive. In contrast, exposure to PM~2.5~ does appear to confer increased risk for SARDs and was a risk factor for JIA in US children below 5.5 years of age. We additionally identified abstracts on ANCA vasculitis \[[@B25]\] and Kawasaki Disease \[[@B26]\], which reported no association with exposure to PM~10~ and PM~2.5~, respectively, although estimates were not provided.

There are several possible reasons for the observed findings. Just as peak incidence of RA varies with age, there may be periods of life where the impact of air pollutants has greater influence on subsequent susceptibility to developing autoimmune diseases. Just as younger patients appeared to be more vulnerable to an association between air pollutants and JIA onset in Zeft et al.\'s study \[[@B23]\], using multivariate analysis controlling for smoking, occupational exposure, home distance to sources of inhaled pollutants, seasonality, and traffic exposure, Orione et al. showed a significant association (odds ratio of 12.2) between carbon monoxide in the third trimester and the subsequent development of juvenile dermatomyositis \[[@B28]\]. Interactions between pollution exposure and specific risk alleles for different autoimmune conditions may also explain the difference in findings of association between air pollutants and different diseases.

Measurement of exposure is another important consideration when interpreting studies of pollution\'s effects on health. Largely, the studies employed place of residence prior to or at diagnosis to determine exposure, without accounting for places where leisure time, occupation, or daily commute might impact risk, resulting in exposure misclassification \[[@B29]\]. The measurement period, duration, and latency period between subclinical and clinical rheumatic diseases might result in wrongfully attributing exposure to the diagnosis period only. The varied composition of air pollution can make it challenging to overcome the confounding effects of concurrent pollutant exposure. Here distance to roadway studies have been conducted \[[@B18], [@B30]\], but further information on which pollutants create this heightened risk is required. Yet another consideration proposed is that the range and variability in pollution levels must be sufficiently large to detect associations, which may allow detection of risks limited to higher exposure levels \[[@B18]\].

Our systematic review included a broad search strategy in order to ensure complete identification of relevant articles. We did not perform a meta-analysis because of the small number of eligible studies identified and their heterogeneity. Our systematic review serves as a valuable resource that highlights methodological considerations that should be considered in future research studies that explore the relationship between air pollution and immune-mediated diseases.

5. Conclusion {#sec5}
=============

The existing studies suggest evidence for possible associations of PM~2.5~ exposure with SARDs development and JIA in younger age cohorts, but the evidence is less clear for links between air pollutant exposures and the development of RA. Additional epidemiologic work is suggested to improve upon existing analysis methods and expand studies of the effects of air pollution on disease phenotype and prognosis. More basic science and translational studies may also help to discover and explain the mechanisms behind progression from pollution related immune stimulation to the formation of antibodies and ultimately to progression of clinically apparent disease.

This work was supported by the Canadian Institutes for Health Research Team Grant: Challenges in Chronic Inflammation Initiative (PI Dr. B. Eksteen).

Search Strategy (Medline) {#secA}
=========================

(1)air pollution^*∗*^/or air pollutant^*∗*^/or air polluted/or air contamination^*∗*^/or atmosphere pollution^*∗*^/or atmosphere pollutant^*∗*^/or atmosphere contamination^*∗*^/or atmospheric pollution^*∗*^/or atmospheric pollutant^*∗*^/or atmospheric contamination^*∗*^/or "particulate matter"/or "PM~10~"/or "PM~2.5~"/or ozone/or "O~3~"/or "carbon monoxide"/or carbonmonoxide/or "CO"/or "nitrogen dioxide"/or "NO~2~"/or "sulphur dioxide"/or "sulphur dioxyde"/or "sulfurous anhydride"/or "SO~2~".ti,ab(2)Air Pollution/or Particulate Matter/or Ozone/or Carbon Monoxide/or Nitrogen Dioxide/or Sulfur Dioxide.sh.(3)Or/(1), (2)(4)Arthritis, Rheumatoid/(5)rheumatoid arthritis.tw.(6)exp Lupus Erythematosus, Systemic/(7)systemic lupus erythematosus.tw.(8)exp Arthritis, Juvenile/(9)juvenile idiopathic arthritis.mp. or juvenile arthritis.tw. \[mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\](10)exp Dermatomyositis/or exp Myositis/or exp Polymyositis/(11)(dermatomyositis or inflammatory myo^*∗*^).mp. or polymyositis.tw. \[mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\](12)exp Scleroderma, Systemic/or exp Rheumatic Diseases/(13)(SARD or systemic autoimmune rheumatic disease or scleroderma).mp. or systemic sclerosis.tw. \[mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier\](14)exp Systemic Vasculitis/or exp Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/or exp Vasculitis/(15)vasculitis.tw.(16)(4) or (5) or (6) or (7) or (8) or (9) or (10) or (11) or (12) or (13) or (14) or (15)(17)(3) and (16).

RA:

:   Rheumatoid arthritis

JIA:

:   Juvenile idiopathic arthritis

SARDs:

:   Systematic autoimmune rheumatic diseases

PM~2.5~:

:   Particulate matter \<2.5 *μ*m in size

PM~10~:

:   Particulate matter \<10 *μ*m in size

SO~2~:

:   Sulfur dioxide

NO~2~:

:   Nitrogen dioxide

CO:

:   Carbon monoxide

O~3~:

:   Ozone

SLE:

:   Systemic lupus erythematosus

RR:

:   Relative risk

HR:

:   Hazard ratio

OR:

:   Odds ratio

95% CI:

:   95% confidence interval

95% CrI:

:   95% Credible Interval.
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###### 

Description of studies included for synthesis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease studied                         Author and year                     Country or region            Type of study                        Sample                                                                                                                      Case definition for diagnosis of rheumatic disease                                                                          Years of study                                               Air pollutants studied                                               Method to determine exposure
  --------------------------------------- ----------------------------------- ---------------------------- ------------------------------------ --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Rheumatoid arthritis                    Chang et al., 2016 \[[@B17]\]       Taiwan                       Cohort                               Population at risk\                                                                                                         Administrative data, 1 ICD-9-CM code for RA                                                                                 2000--2010                                                   NO~2~, PM~2.5~                                                       Monitoring sites
                                                                                                                                                NO~2~ exposure, *n* = 247,419, with *n* = 376 cases; PM~2.5~ exposure, *n* = 244,413, with *n* = 236 cases                                                                                                                                                                                                                                                                                

  De Roos et al., 2014 \[[@B18]\]         British Columbia, Canada            Nested case-control          Controls, *n* = 19,066\              Administrative data, 2 ICD-9 codes for RA with minimum 1 visit to physician specialist                                      1994--2002                                                                                                                  NO~2~, SO~2~, PM~2.5~, PM~10~, CO, NO, black carbon, ozone   Land use regression method for black carbon, PM~2.5~, NO~2~, NO\     
                                                                                                           Cases, *n* = 1,911                                                                                                                                                                                                                                                                                                                                        Inverse distance weighting method for PM~10~, NO, SO~2~, Ozone, CO   

  Hart et al., 2013 \[[@B19]\]            Sweden                              Case-control                 Controls, *n* = 2,536\               Rheumatologist history and exam                                                                                             1996--2008                                                                                                                  NO~2~, SO~2~, PM~10~                                         Land use regression                                                  
                                                                                                           Cases, *n* = 1,497                                                                                                                                                                                                                                                                                                                                                                                                             

  Hart et al., 2013 \[[@B20]\]            USA                                 Cohort                       Population at risk, *n* = 111,425\   Self-report and medical chart review                                                                                        1986--2006                                                                                                                  NO~2~, SO~2~, PM~2.5~, PM~10~                                Land use regression                                                  
                                                                                                           Cases, *n* = 858                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Systemic autoimmune rheumatic disease   Bernatsky et al., 2016 \[[@B21]\]   Quebec and Alberta, Canada   Cohort                               Quebec estimated population at risk, *n* = 7,977,960\                                                                       Administrative data, 2 ICD-9 codes for SARD or 1 ICD-9 code for SARD by a rheumatologist or 1 instance of hospitalization   Quebec, 1996--2011\                                          PM~2.5~                                                              Satellite-derived data of exposure levels at location of residence at time of diagnosis
                                                                                                                                                Estimated cases, *n* = 30,330\                                                                                                                                                                                                                          Alberta, 1993--2007                                                                                                               
                                                                                                                                                Alberta estimated population at risk, *n* = 3,053,980\                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                Estimated cases, *n* = 8,180                                                                                                                                                                                                                                                                                                                                                              

  Bernatsky et al., 2015 \[[@B22]\]       Calgary, Alberta, Canada            Cohort                       Not provided                         Administrative data, 2 ICD-9 codes for SARD or 1 ICD-9 code for SARD by a rheumatologist or 1 instance of hospitalization   1993--2007                                                                                                                  PM~2.5~, NO~2~                                               Land use regression                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Juvenile idiopathic arthritis           Zeft et al., 2009 \[[@B23]\]        USA                          Cohort (case-crossover)              Cases, *n* = 338                                                                                                            Clinical registry                                                                                                           1993--2006                                                   PM~2.5~                                                              Monitoring sites\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          No intercept regression models

  Zeft et al., 2014 \[[@B24]\]            USA and Canada                      Cohort (case-crossover)      Not mentioned in abstract            Not specified                                                                                                               Not mentioned in abstract                                                                                                   PM~2.5~                                                      Selected exposure windows but no mention of extrapolation            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Association between air pollutant exposure and the development of rheumatoid arthritis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                            Study design          Association reported                                Nitrogen dioxide (NO~2~)            Fine particulate matter \< 2.5 microns (PM~2.5~)   Fine particulate matter \< 10 microns (PM~10~)   Sulfur dioxide (SO~2~)
  --------------------------------- --------------------- --------------------------------------------------- ----------------------------------- -------------------------------------------------- ------------------------------------------------ -----------------------------
  Chang et al., 2016 \[[@B17]\]     Cohort                HR^*∗*^ per pollutant level^*∗∗*^                   Q2, 1.12 (95% CI: 0.83 to 1.52);\   Q2, 1.22 (95% CI: 0.85 to 1.74);\                  Not reported                                     Not reported
                                                                                                              Q3, 1.53 (95% CI: 1.12 to 2.90);\   Q3, 1.15 (95% CI: 0.82 to 1.62);\                                                                   
                                                                                                              Q4, 1.52 (95% CI: 1.11 to 2.08)     Q4, 0.79 (95% CI: 0.53 to 1.16)                                                                     

                                                                                                                                                                                                                                                      

  De Roos et al., 2014 \[[@B18]\]   Nested case-control   OR per IQR increase^*∗∗∗*^                          0.90 (95% CI: 0.85 to 0.96)         0.92 (95% CI: 0.87 to 0.98)                        0.91 (95% CI: 0.86--0.96)                        0.88 (95% CI: 0.82--0.93)

                                                                                                                                                                                                                                                      

  Hart et al., 2013 \[[@B19]\]      Case-control          OR per IQR increase over average exposure^*∗∗∗∗*^   0.98 (95% CI: 0.90 to 1.07)         Not reported                                       0.96 (95% CI: 0.88 to 1.04)                      1.01 (95% CI: 0.93 to 1.09)

                                                                                                                                                                                                                                                      

  Hart et al., 2013 \[[@B20]\]      Cohort                HR per IQR range increase^*∗∗∗∗∗*^                  0.92 (95% CI: 0.85 to 1.00)         0.94 (95% CI: 0.86 to 1.04)                        0.92 (95% CI: 0.85 to 0.99)                      0.99 (95% CI: 0.90 to 1.09)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HR: hazard ratio; IQR: interquartile range; OR: odds ratio.

^*∗*^Adjusted for age, sex, urbanization level of residence, monthly income, and chronic obstructive pulmonary disease.

^*∗∗*^NO~2~: Quartile 1, \<66,213 ppm (referent); Quartile 2, 66,213 to 86,908 ppm; Quartile 3, 86,099 to 99,882 ppm; Quartile 4, \>99,992 ppm.

PM~2.5~: Quartile 1, \<10,760 *μ*m/m^3^ (referent); Quartile 2, 10,760 to 12,161 *μ*m/m^3^; Quartile 3, 12,162 to 15,056 *μ*m/m^3^; Quartile 4, \>15,056 *μ*m/m^3^.

^*∗∗∗*^Adjusted for age, sex, and neighborhood socioeconomic status.

^*∗∗∗∗*^Adjusted for age, sex, smoking status, and educational attainment.

^*∗∗∗∗∗*^Adjusted for age, race, smoking status and pack-years of smoking, age at menarche, parity, duration of lactation, menopause, hormone replacement therapy or oral contraceptive use, physical activity, body mass index, parental occupations, education, marital status, husband\'s education, family income, and house value.

###### 

Newcastle-Ottawa scale for quality of study assessment: case-control studies.

  Case-control studies                         Manuscript type   Adequate case definition   Representativeness of cases   Selection of controls   Definition of controls   Comparability of cases and controls   Ascertainment of exposure   Consistency ascertainment   Nonresponse rate   Total
  -------------------------------------------- ----------------- -------------------------- ----------------------------- ----------------------- ------------------------ ------------------------------------- --------------------------- --------------------------- ------------------ --------
  De Roos, Canada, 2014 (RA)                   Full              1^*∗*^                     1^*∗*^                        1^*∗*^                  1^*∗*^                   2^*∗*^                                1^*∗*^                      1^*∗*^                      1^*∗*^             9^*∗*^
  Hart, Sweden, 2013 (RA)                      Full              1^*∗*^                     1^*∗*^                        1^*∗*^                  1^*∗*^                   2^*∗*^                                1^*∗*^                      1^*∗*^                      1^*∗*^             9^*∗*^
  Bernatsky, Alberta and Quebec, 2016 (SARD)   Full              1^*∗*^                     1^*∗*^                        1^*∗*^                  1^*∗*^                   2^*∗*^                                1^*∗*^                      1^*∗*^                      1^*∗*^             9^*∗*^
  Bernatsky, Calgary, 2015 (SARD)              Full              1^*∗*^                     1^*∗*^                        1^*∗*^                  1^*∗*^                   2^*∗*^                                1^*∗*^                      1^*∗*^                      1^*∗*^             9^*∗*^
  Zeft, US, 2009 (JIA)                         Full              1^*∗*^                     1^*∗*^                        1^*∗*^                  0                        1^*∗*^                                1^*∗*^                      1^*∗*^                      1^*∗*^             7^*∗*^
  Zeft, US and Canada, 2014 (JIA)              Abstract          1^*∗*^                     1^*∗*^                        0                       0                        2^*∗*^                                1^*∗*^                      0                           0                  5^*∗*^

For case-control studies, quality was assessed for four domains of selection (case definition, representativeness of cases, selection of controls, and definition of controls), two domains of comparability (study controls for the most important factor and any additional important factor), and three domains of exposure (ascertainment of exposure, same method of ascertainment for cases and controls, and the nonresponse rate). Points are assigned based on specified levels of quality within each domain to a maximum of 9 points.

*∗* denotes the rating system used in the NOS scale.

###### 

Newcastle-Ottawa scale for quality of study assessment: cohort studies.

  Cohort studies             Representativeness of exposed cohort   Selection of nonexposed cohort   Exposure ascertainment   Measured outcome not present at study onset   Comparability of cohorts   Outcome ascertainment   Sufficient Follow-up to allow outcome to occur   Adequacy of follow-up   Total
  -------------------------- -------------------------------------- -------------------------------- ------------------------ --------------------------------------------- -------------------------- ----------------------- ------------------------------------------------ ----------------------- --------
  Chang, Taiwan, 2016 (RA)   1^*∗*^                                 1^*∗*^                           1^*∗*^                   1^*∗*^                                        1^*∗*^                     1^*∗*^                  0                                                1^*∗*^                  8^*∗*^
  Hart, USA, 2013 (RA)       1^*∗*^                                 1^*∗*^                           1^*∗*^                   1^*∗*^                                        2^*∗*^                     1^*∗*^                  1^*∗*^                                           1^*∗*^                  9^*∗*^

For cohort studies, quality is assessed for four domains of selection (representativeness of exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, and demonstration that the outcome of interest was not present at start of study), two domains of comparability (study controls for the most important factor and any additional important factor), and three domains of outcome (method of assessment of outcome, follow-up period, and adequacy of follow-up of cohorts). Points are assigned based on specified levels of quality within each domain to a maximum of 9 points.

*∗* denotes the rating system used in the NOS scale.

[^1]: Academic Editor: Lisa Rider
